Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

2.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

926
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
926
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.6K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

751
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
751
Atypical Pneumonia01:14

Atypical Pneumonia

64
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
64

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of inhaled corticosteroids in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).

Thorax·2025
Same author

Tuberculosis in Poland in 2022.

Przeglad epidemiologiczny·2025
Same author

Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).

The European respiratory journal·2024
Same author

Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).

The European respiratory journal·2024
Same author

Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC).

The Journal of allergy and clinical immunology·2024
Same author

The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study.

Frontiers in public health·2023
Same journal

Infectious diseases in Poland in 2023.

Przeglad epidemiologiczny·2026
Same journal

Foodborne infections and intoxications in Poland in 2021-2023.

Przeglad epidemiologiczny·2026
Same journal

Salmonellosis in Poland in 2023.

Przeglad epidemiologiczny·2026
Same journal

Pertussis in Poland in 2023.

Przeglad epidemiologiczny·2026
Same journal

Lyme disease in Poland in 2023.

Przeglad epidemiologiczny·2026
Same journal

Syphilis in Poland in 2023.

Przeglad epidemiologiczny·2026
See all related articles
  1. Home
  3. Tuberculosis In Poland In 2023.
  1. Home
  3. Tuberculosis In Poland In 2023.

Related Experiment Video

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Tuberculosis in Poland in 2023.

Maria Joanna Korzeniewska-Koseła1, Adam Nowiński1

  • 1Zakład Epidemiologii i Organizacji Walki z Gruźlicą, Instytut Gruźlicy i Chorób Płuc.

Przeglad Epidemiologiczny
|April 14, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Tuberculosis remains a significant public health issue in Poland, with notification rates increasing by 3.5% in 2023. While multidrug-resistant tuberculosis (MDR-TB) and childhood cases are lower than in EU/EEA countries, overall mortality has not decreased.

Keywords:
TB confirmed by cultureTB incidencegruźlicamulti-drug resistancepotwierdzenie bakteriologicznetuberculosis (TB)wielolekoopornośćzapadalność

More Related Videos

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.6K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.6K

Related Experiment Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K
A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

19.6K
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

12.6K

Area of Science:

  • Epidemiology
  • Public Health
  • Infectious Diseases

Background:

  • Tuberculosis (TB) is a major global health concern, affecting millions worldwide.
  • In 2023, TB continued to be a significant public health challenge within the European Union (EU) and European Economic Area (EEA).

Purpose of the Study:

  • To conduct an epidemiological analysis of tuberculosis in Poland for the year 2023.
  • To compare the tuberculosis situation in Poland with that of other EU and EEA countries.

Main Methods:

  • Data were sourced from the National Tuberculosis Register, Statistics Poland, and the NIZP PZH - PIB.
  • Analysis included registered cases, drug susceptibility testing, mortality data, and TB as an AIDS-defining condition.
  • International comparisons utilized a European Centre for Disease Prevention and Control (ECDC) report for EU/EEA countries.

Main Results:

  • Poland registered 4,436 tuberculosis cases in 2023, with a notification rate of 11.3 per 100,000 population.
  • Pulmonary TB constituted 96.1% of cases; 7.9% of cases were of foreign origin, and multidrug-resistant TB (MDR-TB) was found in 3.1% of tested patients.
  • Notification rates increased with age, with higher rates in men. Tuberculosis caused 483 deaths.

Conclusions:

  • Tuberculosis notification rates in Poland increased by 3.5% compared to 2022.
  • Poland reported a lower proportion of MDR-TB and childhood TB cases (<14 years) than the EU/EEA average.
  • Tuberculosis mortality in Poland showed no decrease in 2023.